Advertisement

Topics

EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib

12:35 EDT 19 Jun 2018 | Pharmaceutical Technology

Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib...
Read More...

The post EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib appeared first on Pharmaceutical Technology.

Original Article: EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib

NEXT ARTICLE

More From BioPortfolio on "EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...